Saxenda®, the intended brand name for liraglutide 3 mg, is a once-daily human GLP-1 analogue for the treatment of obesity (Novo Nordisk)
Diabetes News Service
Saxenda®, the intended brand name for liraglutide 3 mg, is a once-daily human GLP-1 analogue for the treatment of obesity (Novo Nordisk)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales